Depression and risk of transformation of episodic to chronic migraine

Sait Ashina, Daniel Serrano, Richard B Lipton, Morris Maizels, Aubrey N Manack, Catherine C Turkel, Michael L Reed, Dawn C Buse, Sait Ashina, Daniel Serrano, Richard B Lipton, Morris Maizels, Aubrey N Manack, Catherine C Turkel, Michael L Reed, Dawn C Buse

Abstract

The aim of this study was to assess the role of depression as a predictor of new onset of chronic migraine (CM) among persons with episodic migraine (EM). The American Migraine Prevalence and Prevention (AMPP) study followed 24,000 persons with severe headache identified in 2004. Using random-effects logistic regression, we modeled the probability that persons with EM in 2005 or 2006 would develop CM in the subsequent year. Depression was assessed in two ways, using a validated questionnaire (PHQ-9 score ≥15) and based on self-reported medical diagnosis. Analyses were adjusted for multiple covariates including sociodemographics, body mass index, headache pain intensity, headache frequency, migraine symptom severity, cutaneous allodynia, acute medication overuse, anti-depressant use and anxiety. Of 6,657 participants with EM in 2005, 160 (2.4 %) developed CM in 2006. Of 6,852 participants with EM in 2006, 144 (2.2 %) developed CM in 2007. In fully adjusted models, PHQ-9 defined depression was a significant predictor of CM onset [odds ratio (OR) = 1.65, 95 % CI 1.12-2.45]. There was a depression-dose effect; relative to participants with no depression or mild depression, those with moderate (OR = 1.77, 95 % CI 1.25-2.52), moderately severe (OR = 2.35, 95 % CI 1.53-3.62), and severe depression (OR = 2.53, 95 % CI 1.52-4.21) were at increased risk for the onset of CM. Among persons with EM, depression was associated with an increased risk of CM after adjusting for sociodemographic variables and headache characteristics. Depression preceded the onset of CM and risk increased with depression severity suggesting a potentially causal role though reverse causality cannot be excluded.

Figures

Fig. 1
Fig. 1
Disposition of subjects during the study. 1 The study base: respondents who provided data in 2005, 2006, 2007 and EM in either 2005 or 2006 or both. 2 1,921 participants with EM in 2006 but not 2005. 3 Of the 6,360 controls in 2006, 5,312 meet ICHD-2 criteria for EM and 1,048 has other outcomes including PM and ETTH. 4 137 subjects with other outcomes were excluded because they developed CM in 2008. 5 The EM subjects in 2006 included 5,331 with EM in 2005 and 2006, and 1,921 subjects with EM in 2006 but not 2005 for a total of 6,852. 6 The 6,708 control subjects in 2007 included 5,212 with EM, 759 with PM, 691 with ETTH and any other outcomes. EM episodic migraine, CM chronic migraine
Fig. 2
Fig. 2
The full disposition of the analysis sample. EM episodic migraine, CM chronic migraine, PM probable migraine, ETTH episodic tension-type headache, CTTH chronic tension-type headache, epi episodic, HA headache
Fig. 3
Fig. 3
Dose–response relationship between severity of depression and risk of developing new-onset CM

References

    1. Headache Classification Subcommittee of the International Headache Society The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9–160.
    1. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:742–746. doi: 10.1111/j.1468-2982.2006.01172.x.
    1. Natoli J, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30:599–609.
    1. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106:81–89. doi: 10.1016/S0304-3959(03)00293-8.
    1. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157–1168. doi: 10.1111/j.1526-4610.2008.01217.x.
    1. Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008;71:848–855. doi: 10.1212/01.wnl.0000325565.63526.d2.
    1. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43:336–342. doi: 10.1046/j.1526-4610.2003.03068.x.
    1. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559–566. doi: 10.1212/01.wnl.0000323925.29520.e7.
    1. Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache. 2001;41:573–578. doi: 10.1046/j.1526-4610.2001.041006573.x.
    1. Buse D, Manack A, Serrano D, Turkel CC, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428–432. doi: 10.1136/jnnp.2009.192492.
    1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–627. doi: 10.1001/archpsyc.62.6.617.
    1. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology. 2003;60:1308–1312. doi: 10.1212/01.WNL.0000058907.41080.54.
    1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–657. doi: 10.1046/j.1526-4610.2001.041007646.x.
    1. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41:638–645. doi: 10.1046/j.1526-4610.2001.041007638.x.
    1. Liebenstein MS, Buse DC, Bigal ME, Grosberg BM, Lipton RB. Development, reliability and validity of the chronic daily headache-computer assisted telephone interview (CDH-CATI) Cephalalgia. 2009;29:78.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88:41–52. doi: 10.1016/S0304-3959(00)00305-5.
    1. Lipton RB, Bigal ME, Ashina S, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63:148–158. doi: 10.1002/ana.21211.
    1. Schafer JL (1997) Analysis of incomplete multivariate data. Chapman & Hall, London
    1. Couch JR, Ziegler DK, Hassanein RS. Evaluation of the relationship between migraine headache and depression. Headache. 1975;15:41–50. doi: 10.1111/j.1526-4610.1975.hed1501041.x.
    1. Zwart JA, Dyb G, Hagen K, et al. Depression and anxiety disorders associated with headache frequency. The Nord-Trondelag Health Study. Eur J Neurol. 2003;10:147–152. doi: 10.1046/j.1468-1331.2003.00551.x.
    1. Bigal ME, Sheftell FD, Rapoport AM, Tepper SJ, Lipton RB. Chronic daily headache: identification of factors associated with induction and transformation. Headache. 2002;42:575–581. doi: 10.1046/j.1526-4610.2002.02143.x.
    1. Ashina S, Lyngberg A, Jensen R. Headache characteristics and chronification of migraine and tension-type headache: a population-based study. Cephalalgia. 2010;30:943–952.
    1. Lopez-Mesonero L, Marquez S, Parra P, Gamez-Leyva G, Munoz P, Pascual J. Smoking as a precipitating factor for migraine: a survey in medical students. J Headache Pain. 2009;10:101–103. doi: 10.1007/s10194-009-0098-2.
    1. Boden JM, Fergusson DM, Horwood LJ. Cigarette smoking and depression: tests of causal linkages using a longitudinal birth cohort. Br J Psychiatry. 2010;196:440–446. doi: 10.1192/bjp.bp.109.065912.
    1. Haynes JC, Farrell M, Singleton N, et al. Alcohol consumption as a risk factor for anxiety and depression: results from the longitudinal follow-up of the National Psychiatric Morbidity Survey. Br J Psychiatry. 2005;187:544–551. doi: 10.1192/bjp.187.6.544.
    1. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004;62:788–790. doi: 10.1212/01.WNL.0000113747.18760.D2.
    1. Lipton RB, Silberstein SD. Why study the comorbidity of migraine? Neurology. 1994;44:S4–S5. doi: 10.1212/WNL.44.11.2215-b.
    1. Baskin SM, Smitherman TA. Migraine and psychiatric disorders: comorbidities, mechanisms, and clinical applications. Neurol Sci. 2009;30(Suppl 1):S61–S65. doi: 10.1007/s10072-009-0071-5.
    1. Klauenberg S, Maier C, Assion HJ, et al. Depression and changed pain perception: hints for a central disinhibition mechanism. Pain. 2008;140:332–343. doi: 10.1016/j.pain.2008.09.003.
    1. Zeng Q, Wang S, Lim G, et al. Exacerbated mechanical allodynia in rats with depression-like behavior. Brain Res. 2008;1200:27–38. doi: 10.1016/j.brainres.2008.01.038.
    1. Ashina S, Bendtsen L, Ashina M, Magerl W, Jensen R. Generalized hyperalgesia in patients with chronic tension-type headache. Cephalalgia. 2006;26:940–948. doi: 10.1111/j.1468-2982.2006.01150.x.
    1. Bigal ME, Ashina S, Burstein R, et al. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology. 2008;70:1525–1533. doi: 10.1212/01.wnl.0000310645.31020.b1.
    1. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain. 2005;9:463–484. doi: 10.1016/j.ejpain.2004.11.001.
    1. Neugebauer V, Li W, Bird GC, Han JS. The amygdala and persistent pain. Neuroscientist. 2004;10:221–234. doi: 10.1177/1073858403261077.
    1. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977;84:191–215. doi: 10.1037/0033-295X.84.2.191.
    1. Boudreau GP, Grosberg BM, McAllister PJ, Sheftell FD, Lipton RB, Buse DC. Open-label, multicenter study of the efficacy and outcome of onabotulinumtoxin-A treatment in patients with chronic migraine and comorbid depressive disorders. J Headache Pain. 2010;11:S50.
    1. Park JW, Lee KS, Kim JS, Kim YI, Shin HE. Genetic contribution of catechol-O-methyltransferase polymorphism in patients with migraine without aura. J Clin Neurol. 2007;3:24–30. doi: 10.3988/jcn.2007.3.1.24.
    1. Blackburn-Munro G, Blackburn-Munro RE. Chronic pain, chronic stress and depression: coincidence or consequence? J Neuroendocrinol. 2001;13:1009–1023. doi: 10.1046/j.0007-1331.2001.00727.x.
    1. Rivat C, Becker C, Blugeot A, et al. Chronic stress induces transient spinal neuroinflammation, triggering sensory hypersensitivity and long-lasting anxiety-induced hyperalgesia. Pain. 2010;150:358–368. doi: 10.1016/j.pain.2010.05.031.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi